ES2181030T3 - Derivados de tetrahidroquinolina como antagonistas de eaa (aminoacidos excitadores). - Google Patents
Derivados de tetrahidroquinolina como antagonistas de eaa (aminoacidos excitadores).Info
- Publication number
- ES2181030T3 ES2181030T3 ES97943809T ES97943809T ES2181030T3 ES 2181030 T3 ES2181030 T3 ES 2181030T3 ES 97943809 T ES97943809 T ES 97943809T ES 97943809 T ES97943809 T ES 97943809T ES 2181030 T3 ES2181030 T3 ES 2181030T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- rent
- alcoxi
- hydrogen
- cor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I) O A UNA SAL, O UN ESTER METABOLICAMENTE LABIL DE LOS MISMOS, DONDE R REPRESENTA UN GRUPO SELECCIONADO A PARTIR DE HALOGENO, ALQUILO, ALCOXI, AMINO, ALQUILAMINO, DIALQUILAMINO, HIDROXI, TRIFLUOROMETILO, TRIFLUOROMETOXI, NITRO, CIANO, SO 2 R 2 O COR 2 , DONDE R 2 REPRESENTA HIDROXI, METOXI, AMINO, ALQUILAMINO, O DIALQUILAMINO; M ES CERO O UN ENTERO DE VALOR 1 O 2; R 1 REPRESENTA UN GRUPO (CH 2 ) N CN, - CH = CHR 3 , (CH 2 ) N NHCOCH 2 R 4 O O(CH SUB,2 ) P NR 5 R 6 ; R 3 REPRESENTA CIANO O EL G RUPO COR 7 ; R 4 REPRESENTA ALCOXI O UN GRUPO NHCOR SUB,8 ; R 5 Y R 6 REPRESENTAN CADA UNO INDEPENDIENTEM ENTE HIDROGENO O ALQUILO, O BIEN REPRESENTAN CONJUNTAMENTE CON EL ATOMO DE NITROGENO AL QUE ESTAN UNIDOS, UN GRUPO HETEROCICLICO; O R 5 ES HIDROGENO Y R 6 ES EL GRUPO COR 9 ; R 7 REPRESENTA UN GRUPO ALCOXI, AMINO O HIDROXILO; R SUB,8 REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO OPCIONALMENTE SUSTITUIDO, ALCOXI, ARILO O HETEROCICLO; R 9 ES ELGRUPO R 8 O EL GRUPO NR 10 R 11 , DONDE R 10 REPRESENTA HIDROGENO O UN GRUPO ALQUILO; R 11 REPRESENTA UN GRUPO ALQUILO OPCIONALMENTE SUSTITUIDO, ARILO, UN GRUPO HETEROCICLICO O CICLOALQUILO; N ES CERO O UN ENTERO DE 1 A 4; P ES UN ENTERO DE 2 A 4. LA INVENCION DESCRIBE ASIMISMO PROCEDIMIENTOS DE PREPARACION DE DICHOS COMPUESTOS Y SU UTILIZACION EN MEDICINA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9617305.9A GB9617305D0 (en) | 1996-08-17 | 1996-08-17 | Heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2181030T3 true ES2181030T3 (es) | 2003-02-16 |
Family
ID=10798623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97943809T Expired - Lifetime ES2181030T3 (es) | 1996-08-17 | 1997-08-14 | Derivados de tetrahidroquinolina como antagonistas de eaa (aminoacidos excitadores). |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6479488B1 (es) |
| EP (1) | EP0922034B1 (es) |
| JP (1) | JP4108129B2 (es) |
| KR (1) | KR100552864B1 (es) |
| CN (1) | CN1131214C (es) |
| AP (1) | AP877A (es) |
| AR (1) | AR008296A1 (es) |
| AT (1) | ATE221052T1 (es) |
| AU (1) | AU724473B2 (es) |
| BR (1) | BR9711311B1 (es) |
| CA (1) | CA2264118C (es) |
| CO (1) | CO4900066A1 (es) |
| CZ (1) | CZ296250B6 (es) |
| DE (1) | DE69714265T2 (es) |
| DK (1) | DK0922034T3 (es) |
| EA (1) | EA001704B1 (es) |
| ES (1) | ES2181030T3 (es) |
| GB (1) | GB9617305D0 (es) |
| HU (1) | HU225797B1 (es) |
| ID (1) | ID18095A (es) |
| IL (1) | IL128141A0 (es) |
| IS (1) | IS4953A (es) |
| MY (1) | MY116952A (es) |
| NO (1) | NO312241B1 (es) |
| NZ (1) | NZ333812A (es) |
| PE (1) | PE107098A1 (es) |
| PL (1) | PL194532B1 (es) |
| PT (1) | PT922034E (es) |
| SI (1) | SI0922034T1 (es) |
| TR (1) | TR199900336T2 (es) |
| TW (1) | TW449582B (es) |
| WO (1) | WO1998007704A1 (es) |
| YU (1) | YU6799A (es) |
| ZA (1) | ZA977326B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9706294D0 (en) * | 1997-03-26 | 1997-05-14 | Glaxo Wellcome Spa | Heterocyclic compound |
| MY125037A (en) * | 1998-06-10 | 2006-07-31 | Glaxo Wellcome Spa | 1,2,3,4 tetrahydroquinoline derivatives |
| US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| GB9929037D0 (en) * | 1999-12-08 | 2000-02-02 | Glaxo Wellcome Spa | Heterocyclic derivatives |
| DE10132725A1 (de) | 2001-07-05 | 2006-08-03 | Grünenthal GmbH | Substituierte γ-Lactonverbindungen |
| WO2003057672A2 (en) * | 2001-12-28 | 2003-07-17 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| WO2004064753A2 (en) * | 2003-01-23 | 2004-08-05 | Acadia Pharmaceuticals Inc | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| US20050250767A1 (en) * | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| WO2004073639A2 (en) * | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| SI1696931T1 (sl) * | 2003-12-22 | 2009-08-31 | Acadia Pharm Inc | Amino substituirani diaril(a,d)cikloheptenski analogi kot muskarinski agonisti in postopki za zdravljenje nevropsihiatričnih motenj |
| US20050282800A1 (en) * | 2004-04-01 | 2005-12-22 | Bo-Ragnar Tolf | Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof |
| RU2451014C2 (ru) * | 2005-07-22 | 2012-05-20 | Мотида Фармасьютикал Ко., Лтд. | Новое производное гетероциклиден ацетамида |
| ES2531621T3 (es) | 2005-07-22 | 2015-03-18 | Mochida Pharmaceutical Co., Ltd. | Derivado de heterociclidenacetamida novedoso |
| AU2006291134C1 (en) | 2005-09-12 | 2013-08-15 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same |
| US9427419B2 (en) | 2005-09-12 | 2016-08-30 | Abela Pharmaceuticals, Inc. | Compositions comprising dimethyl sulfoxide (DMSO) |
| WO2007033180A1 (en) | 2005-09-12 | 2007-03-22 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds |
| US8480797B2 (en) | 2005-09-12 | 2013-07-09 | Abela Pharmaceuticals, Inc. | Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
| WO2007053618A1 (en) * | 2005-10-31 | 2007-05-10 | Acadia Pharmaceuticals Inc. | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| BRPI0921494A2 (pt) | 2008-11-03 | 2018-10-30 | Prad Reasearch And Development Ltd | método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração. |
| US9839609B2 (en) | 2009-10-30 | 2017-12-12 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis |
| AU2012321345B2 (en) | 2011-10-03 | 2016-03-17 | The University Of Utah Research Foundation | Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69029668T2 (de) * | 1989-03-08 | 1997-08-07 | Merck Sharp & Dohme | Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten |
| PL186781B1 (pl) * | 1995-09-29 | 2004-02-27 | Glaxo Wellcome Spa | Nowy związek, pochodna tetrahydrochinoliny, sposób wytwarzania pochodnej tetrahydrochinoliny, środek farmaceutyczny i zastosowanie |
-
1996
- 1996-08-17 GB GBGB9617305.9A patent/GB9617305D0/en active Pending
-
1997
- 1997-08-14 TR TR1999/00336T patent/TR199900336T2/xx unknown
- 1997-08-14 CA CA002264118A patent/CA2264118C/en not_active Expired - Fee Related
- 1997-08-14 WO PCT/EP1997/004440 patent/WO1998007704A1/en active IP Right Grant
- 1997-08-14 AP APAP/P/1999/001459A patent/AP877A/en active
- 1997-08-14 CO CO97046782A patent/CO4900066A1/es unknown
- 1997-08-14 JP JP51037298A patent/JP4108129B2/ja not_active Expired - Fee Related
- 1997-08-14 DE DE69714265T patent/DE69714265T2/de not_active Expired - Lifetime
- 1997-08-14 EA EA199900121A patent/EA001704B1/ru not_active IP Right Cessation
- 1997-08-14 AU AU45518/97A patent/AU724473B2/en not_active Ceased
- 1997-08-14 PE PE1997000718A patent/PE107098A1/es not_active Application Discontinuation
- 1997-08-14 IL IL12814197A patent/IL128141A0/xx not_active IP Right Cessation
- 1997-08-14 EP EP97943809A patent/EP0922034B1/en not_active Expired - Lifetime
- 1997-08-14 DK DK97943809T patent/DK0922034T3/da active
- 1997-08-14 KR KR1019997001280A patent/KR100552864B1/ko not_active IP Right Cessation
- 1997-08-14 MY MYPI97003742A patent/MY116952A/en unknown
- 1997-08-14 ID IDP972834A patent/ID18095A/id unknown
- 1997-08-14 CN CN97197233A patent/CN1131214C/zh not_active Expired - Fee Related
- 1997-08-14 ES ES97943809T patent/ES2181030T3/es not_active Expired - Lifetime
- 1997-08-14 AT AT97943809T patent/ATE221052T1/de not_active IP Right Cessation
- 1997-08-14 US US09/147,568 patent/US6479488B1/en not_active Expired - Fee Related
- 1997-08-14 HU HU9903108A patent/HU225797B1/hu not_active IP Right Cessation
- 1997-08-14 ZA ZA977326A patent/ZA977326B/xx unknown
- 1997-08-14 CZ CZ0052999A patent/CZ296250B6/cs not_active IP Right Cessation
- 1997-08-14 NZ NZ333812A patent/NZ333812A/xx active Application Revival
- 1997-08-14 SI SI9730404T patent/SI0922034T1/xx unknown
- 1997-08-14 YU YU6799A patent/YU6799A/sh unknown
- 1997-08-14 PL PL97331562A patent/PL194532B1/pl not_active IP Right Cessation
- 1997-08-14 BR BRPI9711311-5A patent/BR9711311B1/pt not_active IP Right Cessation
- 1997-08-14 PT PT97943809T patent/PT922034E/pt unknown
- 1997-08-14 AR ARP970103703A patent/AR008296A1/es active IP Right Grant
- 1997-08-30 TW TW086112442A patent/TW449582B/zh not_active IP Right Cessation
-
1999
- 1999-01-22 IS IS4953A patent/IS4953A/is unknown
- 1999-02-16 NO NO19990723A patent/NO312241B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2181030T3 (es) | Derivados de tetrahidroquinolina como antagonistas de eaa (aminoacidos excitadores). | |
| ATE287408T1 (de) | Tricyclische derivate der pyrazolcarbonsäure, ihre herstellung und sie enthaltende pharmazeutische zubereitungen | |
| AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
| BR0109855A (pt) | Derivados de 8-isoquinolinxantina e 8-quinolixantina como inibidores de pde 5 | |
| AR021534A1 (es) | Derivados de 1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion en terapeutica | |
| ES2184772T3 (es) | Derivados de bifenilo, procedimiento para su preparacion y su utilizacion como medicamentos. | |
| EA199800794A1 (ru) | Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения | |
| DK0507672T3 (da) | N-cyclohexylbenzamid-derivater samt deres fremstilling og terapeutiske anvendelse | |
| AU3159701A (en) | Agent for dyeing keratin containing fibers | |
| DK0888337T3 (da) | Piperidon-tachykininantagonister | |
| ES2071666T3 (es) | Derivados de pirazoloisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| EA199900204A1 (ru) | Способы и промежуточные соединения для получения замещенных производных хроманола | |
| ES2172222T3 (es) | Derivados de tetrahidropiridopirimidona 3-substituidos, su obtencion y empleo. | |
| ES2075004T3 (es) | Derivados de pirimidina, procedimientos para su produccion y composiciones herbicidas que los contienen. | |
| ES2027550A6 (es) | Procedimiento para preparar derivados de glicerol. | |
| EA199800701A1 (ru) | БЕНЗО[С]ХИНОЛИЗИНОВЫЕ ПРОИЗВОДНЫЕ, ИХ ПОЛУЧЕНИЕ И ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ 5a-РЕДУКТАЗ | |
| NO161620C (no) | Analogifremgangsm te for fremstilling av terapeutisk aktive 8-alkyltio-2-piperazino-pyrimido(5,4-d)pyrimidin-derivater. | |
| ATE204278T1 (de) | Serotoninergische ergolin derivate | |
| DE69430839T2 (de) | Trizyklische Indol-2-carbonsäure Derivate als selektive NMDA Rezeptor Antagonisten | |
| AR008616A1 (es) | Uso de derivados de fluo-antraciclinona y fluo-antraciclina. | |
| DK469285D0 (da) | Thiadiazolderivater, der indvirker paa centralnervesystemet, fremgangsmaade til fremstilling deraf og midler indeholdende derivaterne | |
| AR005454A1 (es) | Derivados de isooxacefem, su uso, procedimiento para su preparacion y preparaciones farmaceuticas que contienen a dichos derivados. | |
| EP0312245A3 (en) | Polycyclic compounds and pharmaceutical compositions thereof | |
| SE8601013L (sv) | Tricykliska dibensokondenserade derivat och forfarande for deras framstellning | |
| CY1105509T1 (el) | Παραγωγα ινδολιου που διαθετουν ανταγωνιστικες ιδιοτητες των 5ητ2c, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν |